A study based on cell experiments found that the simultaneous inhibition of activated Cdc42-associated kinase (ACK1) and AKT inhibited the growth and migration of KRAS-mutant NSCLC cells, providing the premise for the clinical translation of ACK1 and AKT inhibitors either as monotherapy or with rational combination [128]. Here, TNK2 is linked to non-small cell lung carcinoma.